Five Stocks To Buy Today: Apollo Hospital, Voltas, Crompton, Among Others
Experts have shared their top picks and target levels for these stocks.
Market experts have recommended five stocks to buy today, highlighting their potential for growth and strong performance. Nilesh Jain, Head VP- Technical & Derivatives Research at Centrum Broking Ltd, and Aditya Agarwala, Head of Research and Investments at Invest4edu, have shared their top picks and target levels for these stocks.
Nilesh Jain recommends buying Apollo Hospitals Enterprise Ltd. with a stop loss of Rs 6,970 and a target of Rs 7,380.
Out of 29 analysts tracking the company, 26 maintain a 'buy' rating, two recommend a 'hold,' and one suggest 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an upside of 11%
Jain also recommends buying Voltas Ltd. with a stop loss of Rs 1,288 and a target of Rs 1.365.
Out of 41 analysts tracking the company, 28 maintain a 'buy' rating, eight recommend a 'hold,' and five suggest 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an upside of 10%
His third recommendation is KPIT Technologies Ltd. with a stop loss of Rs 1,376 and a target of Rs 1,465.
Out of 21 analysts tracking the company, 15 maintain a 'buy' rating, four recommend a 'hold,' and two suggest 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an downside of 1.2%
Aditya Agarwala recommends buying Persistent Systems Ltd. with a target of Rs 6,320 and a stop loss of Rs 5,860.
Out of 41 analysts tracking the company, 21 maintain a 'buy' rating, nine recommend a 'hold,' and 11 suggest 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an downside of 7.1%
Agarwala also recommends Crompton Greaves Consumer Electricals Ltd. with a target of Rs 370 and a stop loss of Rs 338.
Out of 39 analysts tracking the company, 36 maintain a 'buy' rating, two recommend a 'hold,' and one suggest 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an upside of 22%
